Showing results (1-10 of 123) with videos related to
Sort By:
Pageof 13
Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission|March 1, 1993
Microwave irradiation for rapid and enhanced immunohistochemical staining: application to skin antigensI van Vlijmen-Willems, P van ErpCancer Treatment Reviews|September 8, 2009
Clinical pharmacokinetics of tyrosine kinase inhibitorsNielka P van Erp, Hans Gelderblom, Henk-Jan GuchelaarCancer Chemotherapy and Pharmacology|December 2, 2021
Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascitesStefanie D Krens, Sasja F Mulder, Nielka P van ErpNederlands Tijdschrift Voor Geneeskunde|December 4, 2014
[Determination of blood levels for oral anticancer drugs]Nielka P van Erp, Winette T A van der GraafClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2021
Pressurized Intraperitoneal Aerosol Chemotherapy: The Road from Promise to ProofLoek A W de Jong, Nielka P van Erp, Lana BijelicBritish Journal of Clinical Pharmacology|May 22, 2019
Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness studySander Zuidema, Ingrid M E Desar, Nielka P van Erp, et al.Cancer Chemotherapy and Pharmacology|April 5, 2021
Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy-naïve patient: a case reportEmmy Boerrigter, Thomas Havenith, Nielka P van Erp, et al.Cancer Chemotherapy and Pharmacology|January 21, 2022
Unintentional combining enzalutamide with a moderate CYP2C8 inhibitor in a patient with metastatic castration-resistant prostate cancer: a case reportS H Verhulst, E Boerrigter, S Ras, et al.Drug Discovery Today|September 24, 2014
Individualized dosing of tyrosine kinase inhibitors: are we there yet?Djoeke de Wit, Henk-Jan Guchelaar, Jan den Hartigh, et al.Expert Review of Molecular Diagnostics|October 3, 2019
Clinical utility of emerging biomarkers in prostate cancer liquid biopsiesEmmy Boerrigter, Levi N Groen, Nielka P Van Erp, et al.Pageof 13